By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Genesis Marks 10th Anniversary With Magma GT Concept Aimed at High-Performance Flagships - 2It's been 20 years since MTV's golden couple split. These producers saw it all unravel.
- 3Heart disease risk greater for women with a common condition they may not be aware they have
- 4Figure out How to Involve a Brain science Certification in Showcasing
- 5Cannabis reclassification could 'open the floodgates' for research, scientists say
- Explainer-What will change with the US reclassification of marijuana?
- James Webb Space Telescope spies mysterious high-energy radiation in star nursery
- Pentagon advances Golden Dome missile defense with new Space Force contracts
- Aspirin can prevent a serious pregnancy complication — but too few women get it, new report suggests
- Is relief in sight? Flu season still brutal but cases are declining.
- How comfort foods trigger pleasure in our brains
- An Investigate of 6 Creative Specialty Mixed drinks
- 5 things for parents to know about changes to kids vaccine schedule
- Europe pledges over €15bn for clean energy for Africa
